Antibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN2841632 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Dual-Specificity tyrosine-(Y)-phosphorylation Regulated Kinase 2 (DYRK2) (AA 105-135), (N-Term) antibody
- Antibody type
- Polyclonal
- Description
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- AA 105-135, N-Term
- Antibody clone number
- RB3008
- Vial size
- 80 μL
- Storage
- Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Submitted references Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy.
Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer.
Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways.
DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.
DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer.
Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma.
Nomura S, Suzuki Y, Takahashi R, Terasaki M, Kimata R, Terasaki Y, Hamasaki T, Kimura G, Shimizu A, Kondo Y
BMC urology 2015 Jun 19;15:53
BMC urology 2015 Jun 19;15:53
Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer.
Enomoto Y, Yamashita S, Yoshinaga Y, Fukami Y, Miyahara S, Nabeshima K, Iwasaki A
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014 Nov;35(11):11021-5
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014 Nov;35(11):11021-5
Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways.
Pérez M, García-Limones C, Zapico I, Marina A, Schmitz ML, Muñoz E, Calzado MA
Journal of molecular cell biology 2012 Oct;4(5):316-30
Journal of molecular cell biology 2012 Oct;4(5):316-30
DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.
Taira N, Mimoto R, Kurata M, Yamaguchi T, Kitagawa M, Miki Y, Yoshida K
The Journal of clinical investigation 2012 Mar;122(3):859-72
The Journal of clinical investigation 2012 Mar;122(3):859-72
DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer.
Yamashita S, Chujo M, Moroga T, Anami K, Tokuishi K, Miyawaki M, Kawano Y, Takeno S, Yamamoto S, Kawahara K
Anticancer research 2009 Jul;29(7):2753-7
Anticancer research 2009 Jul;29(7):2753-7
Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma.
Yamashita S, Chujo M, Tokuishi K, Anami K, Miyawaki M, Yamamoto S, Kawahara K
The Journal of thoracic and cardiovascular surgery 2009 Dec;138(6):1303-8
The Journal of thoracic and cardiovascular surgery 2009 Dec;138(6):1303-8
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC